Europe Genetic Testing Market Size and Forecast 2025–2033: A New Era of Precision Healthcare

Europe Genetic Testing Market Outlook

The Europe Genetic Testing Market is entering a powerful phase of transformation, fueled by advances in genomics, rising awareness of hereditary diseases, and strong government backing for precision medicine. According to Renub Research, the market is expected to grow from US$ 6.20 billion in 2024 to US$ 12.50 billion by 2033, expanding at a CAGR of 8.10% from 2025 to 2033.

Download Free Sample Report

This impressive growth reflects how genetic testing has moved from a niche medical service to a mainstream diagnostic and preventive tool across Europe. From oncology and prenatal screening to pharmacogenomics and rare disease detection, genetic testing is now reshaping how diseases are diagnosed, treated, and even prevented.

What Is Genetic Testing and Why It Matters

Genetic testing involves examining DNA, chromosomes, or proteins to identify changes or mutations linked to diseases or health conditions. These tests can:

Predict disease risk

Confirm diagnoses

Guide treatment decisions

Support family planning

Enable personalized medicine

Samples are typically collected from blood, saliva, or tissue. While the scientific benefits are enormous, genetic testing also raises ethical, psychological, and privacy concerns—making genetic counseling a critical part of the process both before and after testing.

In Europe, genetic testing is becoming a cornerstone of modern healthcare systems, supported by advanced infrastructure, strong research ecosystems, and forward-thinking public health policies.

Europe Genetic Testing Market Overview

Europe’s genetic testing market is expanding rapidly due to:

Increased prevalence of genetic and chronic diseases

Aging population

Growing use of genetic testing in cancer and rare diseases

Technological advancements like next-generation sequencing (NGS)

Rising demand for direct-to-consumer (DTC) genetic tests

Government support for genomic research

Countries such as Germany, the UK, and France dominate the regional market thanks to robust healthcare systems, strong regulatory frameworks, and early adoption of genomic medicine. At the same time, Southern and Eastern European countries are catching up through investments in healthcare modernization.

Key Growth Drivers of the Europe Genetic Testing Market

1. Rising Incidence of Chronic and Hereditary Diseases

The increasing burden of cancer, cardiovascular disorders, and genetic conditions is one of the strongest drivers of genetic testing demand in Europe. Genetic testing enables early detection, risk assessment, and targeted therapies—particularly in oncology.

According to European cancer projections, the number of new cancer cases is expected to exceed 3 million annually by the late 2030s, creating a strong need for molecular diagnostics and companion genetic tests. As awareness of genetic predisposition grows, both patients and clinicians are turning to genetic testing for better outcomes and personalized treatment plans.

2. Growing Public Awareness and Preventive Healthcare Trends

European consumers are becoming more proactive about their health. Media coverage, digital health platforms, and wellness campaigns have significantly increased awareness of genetic risks and preventive testing.

Direct-to-consumer genetic testing has played a major role in this shift, allowing individuals to access insights about ancestry, disease risk, and lifestyle compatibility. Younger, tech-savvy populations are especially driving demand for genomics-based wellness and prevention solutions, pushing genetic testing beyond hospitals into everyday life.

3. Technological Advancements in Genetic Testing

Innovation is reshaping the genetic testing landscape. Technologies such as:

Next-generation sequencing (NGS)

CRISPR-based analysis

AI-driven genomic interpretation

have made testing faster, more accurate, and more affordable.

These advances now allow whole-genome and whole-exome sequencing to be performed at scale, unlocking deeper insights into complex diseases. Strategic partnerships between biotech firms and research institutions are also accelerating market expansion.

For example, Myriad Genetics expanded its MyChoice CDx Plus Testing in Germany and France through partnerships with specialized diagnostic institutes—highlighting how collaborations are improving access to advanced genomic solutions.

Challenges Facing the Europe Genetic Testing Market

High Cost of Advanced Genetic Tests

Despite technological progress, advanced tests such as whole-genome sequencing remain expensive. Reimbursement policies vary widely across Europe, creating access disparities between countries and healthcare systems. For many patients, cost remains a barrier—particularly outside major urban centers.

Regulatory Complexity Across Europe

Europe’s fragmented regulatory landscape presents a major challenge. While EU-wide frameworks such as GDPR and IVDR exist, individual countries still maintain unique healthcare policies, reimbursement rules, and approval processes.

This complexity increases operational costs, delays product launches, and complicates cross-border expansion for genetic testing providers.

Country-Level Market Insights

France Genetic Testing Market

France is rapidly emerging as a leader in European genomic medicine. The government’s “Genomic Medicine France 2025” initiative is accelerating adoption of next-generation sequencing across public hospitals.

Genetic testing demand is particularly strong in oncology, rare diseases, and prenatal screening. Growing acceptance of direct-to-consumer testing further supports market growth, despite ongoing debates around data privacy and reimbursement.

Germany Genetic Testing Market

Germany’s genetic testing market is one of the fastest-growing in Europe, driven by:

Strong healthcare infrastructure

Government-funded genomic research

Industry-academia collaborations

Product launches and partnerships continue to expand test availability. For example, Genetic Analysis AS introduced the GA-map Dysbiosis Test in Germany to standardize microbiome analysis, while Blueprint Genetics partnered with BioMarin to expand testing for skeletal dysplasia.

United Kingdom Genetic Testing Market

The UK has become a global model for genetic testing integration. The NHS nationwide genetic testing program, launched in 2022, enables rapid diagnosis of over 6,000 genetic diseases in newborns and children.

This initiative significantly boosts demand for clinical genetic testing and strengthens the UK’s leadership in genomic medicine, especially in rare diseases and oncology.

Spain Genetic Testing Market

Spain’s market growth is supported by government investment, improved healthcare access, and rising public awareness. Next-generation sequencing is now widely used in oncology, neonatal screening, and rare disease diagnosis.

The increasing popularity of DTC genetic tests is also expanding consumer access to genomic insights, further accelerating market expansion.

Europe Genetic Testing Market Segmentation

By Type

Predictive Testing

Carrier Testing

Prenatal and Newborn Testing

Diagnostic Testing

Pharmacogenomic Testing

Nutrigenomic Testing

Others

By Product

Consumables

Equipment

Software & Services

By Technology

PCR

DNA Sequencing

Microarrays

Others

By Disease

Cancer

Genetic Diseases

Cardiovascular Diseases

Rare Diseases

Infectious Diseases

Others

By End User

Hospitals & Clinics

Diagnostic Laboratories

Others

By Country

France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Russia, Poland, Greece, Norway, Romania, Portugal, and Rest of Europe.

Competitive Landscape: Key Players Driving Innovation

The European genetic testing market is highly competitive and innovation-driven. Leading companies are investing in technology upgrades, partnerships, and geographic expansion.

Key players include:

Abbott Laboratories

Danaher Corporation (Cepheid Inc.)

Illumina Inc.

Bio-Rad Laboratories Inc.

F. Hoffmann-La Roche AG

DiaSorin

Revvity Inc.

Thermo Fisher Scientific Inc.

Each company is analyzed across:

Company overview

Key decision-makers

Recent developments & strategies

Sales analysis

Final Thoughts: The Future of Genetic Testing in Europe

The Europe genetic testing market is moving rapidly toward a future defined by precision healthcare and personalized medicine. With strong government initiatives, continuous technological innovation, and rising public awareness, genetic testing is becoming an integral part of preventive and clinical care.

While challenges such as cost and regulatory complexity remain, ongoing collaboration between governments, healthcare providers, and biotech companies will likely overcome these barriers. As genetic insights become more accessible, Europe is set to lead the global shift toward predictive, preventive, and personalized healthcare.